Anthony Mato, MD, MSCE
Director, CLL Program
Chronic Lymphocytic Leukemia (CLL); Lymphoproliferative Disorders
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Mato accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, SUNY Buffalo; MSCE, University of Pennsylvania School of Medicine
Internal Medicine - Hospital of the University of Pennsylvania
Hematology and Oncology - Hospital of the University of Pennsylvania
Internal Medicine; Hematology and Oncology
My primary focus is providing excellent care to people with chronic lymphocytic leukemia (CLL). At MSK, I serve as Director of the CLL Program. I oversee a team of experts who are entirely dedicated to all aspects of diagnosing and treating CLL. Our combined expertise allows us to develop the best treatment plans tailored to each patient’s unique situation. We can safely administer current therapies and also provide access to the newest treatments through clinical trials. Our mission is to provide people with CLL with state-of-the-art monitoring and treatments through clinical research and expertise.
- Clinical Trials Investigated by Dr. Mato
- A Phase I Study of Epcoritamab in People with Relapsed or Persistent Chronic Lymphocytic Leukemia
- A Phase I/II Study of LOXO-305 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
- A Phase IB Study of Mosunetuzumab in People with Recurrent or Persistent Chronic Lymphocytic Leukemia
- A Phase II Study Assessing Limited Treatment Time with Acalabrutinib Combined with Obinutuzumab in People Newly Diagnosed with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- A Phase II Study of DTRMWXHS-12, Everolimus, and Pomalidomide in People with Recurrent or Persistent Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma
- A Phase II Study of Venetoclax and Obinutuzumab as Initial Therapy for Chronic Lymphocytic Leukemia
- A Phase III Study of Panzyga to Prevent Infection in People with Chronic Lymphocytic Leukemia
- A Phase III Study of Venetoclax and Rituximab with and without Pirtobrutinib for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- A Study Assessing Minimal Residual Disease to Minimize Side Effects in People with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Were Treated with Venetoclax
- Clinical Trials Co-Investigated by Dr. Mato
- A Phase I Study of LOXO-338 in People with B-Cell Lymphomas
- A Phase I Study of ME-401 in Patients with Recurrent or Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia or Follicular Lymphoma
- A Phase I Study of PSB202 in People with Recurrent or Persistent Indolent B-Cell Lymphoma
- A Phase II Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Leukemia
- A Phase III Study Assessing Early versus Delayed Treatment with Venetoclax and Obinutuzumab for Newly Diagnosed Patients with High-Risk Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma without Symptoms
- A Phase III Study of LOXO-305 versus Standard Treatment for Persistent Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Mato AR, Nabhan C, Barr PM, Ujjani CS, Hill BT, Lamanna N, Skarbnik AP, Howlett C, Pu J, Sehgal AR, Strelec LE, Vandegrift A, Fitzpatrick DM, Zent CS, Feldman T, Goy A, Claxton DF, Bachow SH, Kaur G, Svoboda J, Nasta SD, Porter D, Landsburg DJ, Schuster SJ, Cheson BD, Kiselev P, Evens AM. Outcomes of CLL patients treated with sequential kinase inhibitor therapy: A real world experience. Blood. 2016 Nov 3;128(18):2199-2205. doi: 10.1182/blood-2016-05-716977
Mato A, Nabhan C, Kay NE, Weiss MA, Lamanna N, Kipps TJ, Grinblatt DL, Flinn IW, Kozloff MF, Flowers CR, Farber CM, Kiselev P, Swern AS, Sullivan K, Flick ED, Sharman JP. Real-world clinical experience in the Connect® CLL registry: a prospective cohort study of 1494 patients across 199 US centres. British Journal of Hematology. 2016 Dec;175(5):892-903. doi: 10.1111/bjh.14332
Mato AR, Hill BT, Lamanna N, Barr PM, Ujjani CS, Brander DM, Howlett C, Karbnik AP, Cheson BD, Zent CS, Pu JJ, Kiselev P, Foon K, Lenhart J, Henick Bachow S, Winter AM, Cruz AL Claxton DF, Goy A, Daniel C, Isaac K, Kennard KH, Timlin C, Fanning M, Gashonia L, Yacur M, Svoboda J, Schuster SJ, Nabhan C. Optimal Sequencing of Ibrutinib, Idelalisib, and Venetoclaxin Chronic Lymphocytic Leukemia: Results from a Multi-Center Study of 683 Patients. Annals of Oncology. 2017 May 1;28(5):1050-1056. doi: 10.1093/annonc/mdx031
Mato AR, Thompson MC, Nabhan C, Svoboda J, Schuster S. Chimeric antigen receptor T-cell therapy for chronic lymphocytic leukemia: a narrative review. Clinical Lymphoma Myeloma and Leukemia. 2017 Dec;17(12):852-56. doi: 10.1016/j.clml.2017.07.007
Jones JA, Mato AR, Wierda WG, Davids MS, Choi M, Cheson BD, Furman RR, Lamanna N, Barr PM, Zhou L, Chyla B, Salem AH, Verdugo M, Humerickhouse RA, Potluri J, Coutre S, Woyach J, Byrd JC. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncology. 2018;19(1):65-75.
Mato AR, Clasen S, Pickens P, Gashonia L, Rhodes J, Svoboda J, Hughes M, Nabhan C, Ali N, Schuster S, Carver J. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia. Cancer Biology and Therapy. 2018 Jan;19(1):1-2. doi: 10.1080/15384047.2017.1394554
Mato AR, Nabhan C, Thompson MC, Lamanna N, Brander D, Hill B, Howlett C, Skarbnik A, Cheson B, Zent C, Pu J, Kiselev P, Goy A, Claxton A, Isaack K, Kennard K, Timlin C, Landsburg D, Winter A, Nasta S, Bachow S, Schuster S, Dorsey C, Svoboda J, Barr P, Ujjani C.Toxicities and outcomes of 621 ibrutinib-treated chronic lymphocytic leukemia patients in the United States: a real-world analysis. Haematologica (accepted, publication pending).
Mato AR, Islam P, Daniel C, Strelec L, Kaye AH, Brooks S, Ganetsky A, Nasta S, Porter DL, Svoboda J, Nabhan C, Schuster SJ. Ibrutinib-induced pneumonitis in patients with chronic lymphocytic leukemia. Blood. 2016 Feb 25;127(8):1064-7. doi: 10.1182/blood-2015-12-686873
Wang J, Morrissette J, Lieberman DB, Timlin C, Schuster SJ, Mato AR. Utilization of Next Generation Sequencing Identifies Potentially Actionable Mutations in Chronic Lymphocytic Leukaemia. British Journal of Hematology. 2016 Oct 7. doi: 10.1111/bjh.14315
O’Brien S, Jones JA, Coutre SE, Mato AR, Hillmen P, Tam C, Österborg A, Siddiqi T, Thirman MJ, Furman RR, Ilhan O, Keating MJ, Call TG, Brown JR, Stevens-Brogan M, Li Y, Clow F, James DF, Chu AD, Hallek M, Stilgenbauer S. Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncology. 2016 Oct;17(10):1409-1418. doi: 10.1016/S1470-2045(16)30212-1
Visit PubMed for a full listing of Dr. Mato’s journal articles. Pubmed is an online index of research papers and other articles from the US National Library of Medicine and the National Institutes of Health.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Anthony Mato discloses the following relationships and financial interests:
Provision of Services
Merck & Co Inc.
Provision of Services
Provision of Services
Provision of Services
Provision of Services
Provision of Services
TG Therapeutics, Inc
Provision of Services
Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2020 through disclosure submission in spring 2021). This data reflects interests that may or may not still exist. This data is updated annually.